Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism

Kaczyńska, Anna; Pelsers, Maurice M.A.L.; Bochowicz, Anna; Kostrubiec, Maciej; Glatz, Jan F. C.; Pruszczyk, Piotr

doi:10.1016/j.cca.2006.02.032

Cited by 113 publications

(94 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there are limited data on the use of different biomarkers in predicting mortality in patients with acute PE. In patients with acute PE, elevated concentrations of brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP), circulating heart-type fatty acid-binding protein (H-FABP), tenascin-C, growth differentiation factor-15 (GDF-15), and D-dimer on admission have been shown to be helpful to identify patients at risk of death or adverse clinical outcome during the acute phase of PE [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Jenab

Pourjafari

Sotoudeh

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Acute pulmonary embolism (PE) is a cardiovascular challenge with potentially fatal consequences.This study was designed to observe the association of novel cardiac biomarkers with outcome in this setting. In this prospective study, from 86 patients with a confirmed diagnosis of PE, 59 patients met the inclusion criteria (22 men, 37 women; mean age, 63.36±15.04 y). The plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), tenascin-C, and D-dimer were measured at the time of confirmed diagnosis. The endpoints of the study were defined as the short-term adverse outcome and long-term all-cause mortality.Totally, 11.8% (7/59) of the patients had the short-term adverse outcome. The mean value of logNT-proBNP was 6.40±1.66 pg/ml. Among all the examined biomarkers, only the mean value of logNT-proBNP was significantly higher in the patients with the short-term adverse outcome (7.88±0.67 vs 6.22± 1.66 pg/ml; OR, 2.359; 95% CI, 1.037 to 5.367; p=0.041). After adjustment, a threefold increase in the short-term adverse outcome was identified (OR, 3.239; 95% CI, 0.877 to 11.967; p=0.078). Overall, 18.64% (11/59) of the patients had expired by the long-term follow-up. Moreover, adjustment revealed an evidence regarding association between increased logNT-proBNP levels and longterm mortality (HR, 2.163; 95%CI, 0.910 to 5.142; p=0.081).Our study could find evidences on association between increased level of NT-proBNP and short-term adverse outcome and/or long-term mortality in PE. This biomarker may be capable of improving prediction of outcome and clinical care in non-high-risk PE.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Jenab

Pourjafari

Sotoudeh

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…H-FABP remained a superior prognostic indicator even when compared with the maximal NT-proBNP and troponin levels over the first 24 h post-patient admission [15]. The superiority of H-FABP over troponin and myoglobin for risk stratification in acute PE has also been shown by KACZYNSKA et al [16]. The fact that H-FABP appears to be an early and promising indicator of right ventricular dysfunction and injury, following acute lung vascular decompensation, has provided a strong rationale for investigating its potential usefulness in CTEPH.…”

mentioning

confidence: 65%

Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein

Orfanos¹,

Zakynthinos²

2008

European Respiratory Journal

View full text Add to dashboard Cite

“…Yapılan başka çalışmalarda, kısa dönem ölümleri göstermede, birçok değişken arasında sadece H-FABP'ın bağımsız bir belirleyici olduğu gösterilmiştir 64,65 . Dellas ve ark'ları, H-FABP'nın sadece 30 günlük mortaliteyi değil aynı zamanda uzun dönem prognonuzu göstermede bağımsız bir belirleyici olduğunu tespit ettiler 66 .…”

Section: Kalp Tipi Yağ Asidi Bağlayıcı Proteinunclassified

“…Dellas ve ark'ları, H-FABP'nın sadece 30 günlük mortaliteyi değil aynı zamanda uzun dönem prognonuzu göstermede bağımsız bir belirleyici olduğunu tespit ettiler 66 . Konu ile alakalı yapılan çalışmaların hemen hepsinde, H-FABP'ın oldukça yüksek NPD (%99-%100) ile PPD (%28-%71)'e sahip olduğu saptanmıştır [64][65][66][67] . Ayrıca yapılan çalışmalarda, H-FABP'ın kısa dönem prognostik etkinliğinin cTn, BNP, EKO ve BT bulgularından daha değerli olduğu gösterilmiştir 66,67 .…”

Section: Kalp Tipi Yağ Asidi Bağlayıcı Proteinunclassified

Pulmoner Embolide Şiddet ve Prognozun Değerlendirilmesi

Kılıç¹

2014

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Although technology of diagnosis and treatment continues to improve, the mortality rate of pulmonary embolism remains high. It was detected that more than 10% of the hospital mortality is related to pulmonary embolism. Really, management of this disease is hard. It is a consensus that patients with massif pulmonary embolism, which is characterized hemodynamic impairment, and have indications of aggressive treatments such as thrombolytic. But the issue of treatment of the hemodynamically stable patients with pulmonary embolism accompanied by right ventricular dysfunction is not clear. In last year, because of the cost-effectiveness, it has been reported that lowrisk patients could treated as outpatients. Hence, it is need to make an accurate judgment of pulmonary embolism severity and prognosis. Biomarkers such as brain natriuretic peptide, N-terminal probrain natriuretic peptide, cardiac troponin, and heart-type fatty acid-binding protein are very important indicators of pulmonary embolism severity and short-term prognosis. Furthermore, it was reported that the pulmonary embolism severity index and simplified pulmonary embolism severity index are more suitable assessing the overall mortality and long-term prognosis. It is suggested that they could be used especially in identifying low risk group. In this review, in the recent literature, it will be assessed biomarkers, findings right ventricular dysfunction which were detected by imaging tool, and a few clinical prognostic model for evaluating pulmonary embolism severity and prognosis. Key words: Biomarker; pulmonar mebolis; pulmonary embolism severity index; prognosis; risk evaluation ÖZET Tanı ve tedavideki teknolojik gelişmelere rağmen, pulmoner emboliye bağlı mortalite halen yüksektir. Hastane ölümlerinin %10'dan fazlası pulmoner emboli ile alakalı olduğu tespit edilmiştir. Gerçekten,

show abstract

Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism

Cited by 113 publications

References 26 publications

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein

Pulmoner Embolide Şiddet ve Prognozun Değerlendirilmesi

Contact Info

Product

Resources

About